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Background: Mesenchymal stem cells (MSC) are unique in their ability to self-renew and differentiate 
into one of many lineage possibilities. It is therefore integral to preserve these qualities to prevent the far 
reaching effects of a defective stem cell. Human mesenchymal stem cells (hMSC) are precursors for and 
can differentiate into osteoblasts, adipocytes and chondrocytes. They were originally found in the bone 
marrow, but have also been located in the umbilical cord, adipose tissue and muscle. Few studies have 
been conducted into the in vivo effects of age on these cells. This contribution reviews current knowledge 
surrounding the effects of age on the characterisation and differentiation of human mesenchymal stem 
cells. 
Methods: 471 articles were found using a combination of Online published articles from January 1983 to 
January 2016 were searched using the Cochrane Library, PubMed, Medline, Scopus, Web of Science and 
Science Direct databases. There were no existing systematic reviews on this research topic. 
Results: Nine studies were identified that met the predefined selection criteria. Three studies were used to 
assess the effects of ageing on characterisation of hMSC with no conclusive results. The cumulative 
results of these studies show that the effect of ageing on characterisation of hMSC remains inconclusive. 
Seven studies were used to assess the differentiation potentials of hMSC showing that age either 
decreased or altered lineage preference in hMSC differentiation.   
Conclusion: There is indication that ageing affects hMSC characterisation and differentiation, however it 
is not conclusive. There are not enough high quality controlled clinical trials to make reliable conclusions. 















The effects of age on human cells has long been an area of scientific interest as well as of significant importance 
to the general population. In particular, mesenchymal cells have been identified as key progenitor cells affected 
by the ageing process. Bone marrow derived stem cells for non-haematopoietic tissues are generally known as 
mesenchymal stem cells (MSC)
 
[1]. Mesenchymal stem cells (hMSC) are characterised as being plastic 
adherent, non-hematopoietic cells that reside in a perivascular niche in the bone marrow stroma, that possess 
self-regeneration and multi-lineage differentiation capacity[2,3].  
hMSC are known to be found in the bone marrow, but are also present in umbilical cord blood, placenta, foetal 
liver, lung, corneal stroma, adult muscle and deciduous infant teeth [4,5]. The accuracy of the term 
“mesenchymal” has been disputed as it should encompass both blood and connective tissue lineages[6], 
 however, they only produce connective tissue cells. In addition, there have been different names ascribed to 
hMSC such as skeletal or stromal stem cells (SSC); but for the purpose of this review the term mesenchymal 
stem cell (MSC) will be used [7]. 
The difference between the mesenchymal and haematopoetic stem cell lineages are shown in (Figure 1). Both 
cells exist in the bone marrow where they differentiate to follow their lineage progression through intermediate 
progenitors to terminally differentiated cells such as osteoblasts, adipocytes and chrondrocytes. In addition, 
some hMSC are hypothesized to become non-adherent osteoprogenitor cells which can be mobilised for distal 
bone growth or fracture repair[8] .  
 
Figure 1 The lineage differentiation of mesenchymal and haematopoietic stem cells [8]. 
The characterisation criteria of mesenchymal stem cells have been standardised by The International Society for 
Cellular Therapy (ISCT) who outline the following criteria for the characterisation of hMSC: (1) adherence to 
plastic; (2) differentiation into chondrocytes, osteoblasts, and adipocytes under standard in vitro differentiating 
conditions; and (3) expression of surface markers CD105, CD73, and CD90, in the absence of haematopoietic 
markers CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR. The criteria are not ideal for in vivo 
models, though they are apt for in vitro experimentation [9,10].  
Research has shown that MSCs form into their specific descendants due to lineage specific transcription factors. 
Differentiation into osteoblasts requires Runt-related transcription factor-2 and Osterix which regulate 
osteogenesis and some cartilage formation. Whereas differentiation into adipocytes requires the presence of the 
nuclear hormone receptor transcription factor Peroxisome proliferator-activated receptor-γ (PPARγ) and the 
CAAT/enhancer binding protein-α (C/EBPα). The chondrocyte is transcribed by the presence of SRY-box 
containing gene 9 (SOX9) [11]. 
Studies of the ageing process of hMSC indicate three types of aging modifications seen in hMSC: (1) changes in 
quantity, (2) changes in quality (differentiation/regeneration capacity) and (3) changed mobilization capacity 
 [8]. Further subdivisions can be made into MSC types by how they are affected by the ageing process as 
compared to somatic cells. This is based on the following characteristics (Table 1): differentiation potential, 
abilitiy to senesce, telomerase activity and self renewal. These types are known as the deteriorating MSC, the 
persistent MSC and the rarer perennial MSC which is able to avoid the ageing process altogether. The formation 
of the subdivisional types is dependent on external factors such as oxidative stress, genetic aberration and the 
quantity of transcriptional stimuli. The accumulation of aged hMSC then cause compromise of tissues and 
organs due to their diminishing ability to create more progeny [12,13,14]. 
 
 Somatic Cells Deteriorating MSC Persistent MSC Perennial MSc 
Differentiation 
potential 
None Some Some Great 
Senescence  Yes Yes Yes No 
Telomerase Inactive Inactive Potential Active 
Self-Renewal No No Yes Yes 
Examples Sozou and 
Kirkwood (2001) 
Simonsen et al. 
(2002) and 
Stenderup et al. 
(2003) 
Pittenger et al. 
(1999) and 
Schieker et al. 
(2004) 
Jiang et al. (2002) 
and Yoon et al. 
(2005) 
 
Table 1 Hypothetical classification of age behaviour of different subsets in adult stem cells. 
[15,16,17,18,19,20,21,22] 
However, it is not known whether the ageing of MSCs is caused by intrinsic or external factors [23,24]. 
Reduced proliferation of hMSC could be caused by intrinsic factors such as hMSC with markers for senescence-
associated b-galactosidase increased expression of p53 and its genes (p21 and BAX). Whereas external factors 
could be reduced synthesis of proteoglycans, glycosaminoglycans and reactive oxygen species which 
compromise cell viability and have the ability to trigger apoptosis [25,26, 27]. 
Method 
This systematic review followed the PRISMA guidelines with the following pathway outcomes.  
 
 Figure 2 – Search pathway for review. 
Search 
Online published articles from January 1983 to January 2016 were searched using the Cochrane Library, 
PubMed, Medline, Scopus, Web of Science and Science Direct databases. The initial literature search in 
Cochrane yielded 0 results. Instead, we used MeSH-terms (Medical Subject Headings, controlled vocabulary 
thesaurus used for indexing articles) in the other databases: “Ageing”[Mesh] AND “human mesenchymal stem 
cells”[Mesh]; “Ageing” AND “Characterisation and Differentiation”[Mesh] AND “human mesenchymal stem 
cells,”[Mesh]. Limits were set for: “language English,” “humans,” and “full text available,” There were no 
existing systematic reviews on this research topic. Unpublished studies were searched for in the clinical trial 
registries and a hand search was conducted of additional articles using the same search terms as mentioned 
above. 
Selection Criteria 
Studies were selected based on the following inclusion criteria: (1) original research papers with prospective or 
retrospective design (double- blind, placebo-controlled or randomized controlled trials [RCTs], observational 
studies, population-based studies, cohort studies), (2) studies used the International Society for Cellular Therapy 
(ISCT) characterisation criteria 3) English language, (4) carried out in humans, (5) published in an peer-
reviewed journal, and (6) full text available. 
Studies were excluded in case of: (1) not using ISCT criteria for characterisation. 
Results 
471 articles were identified and of those nine studies were selected through the inclusion and exclusion criteria. 
Both the effects of ageing on the 1) Characterisation of mesenchymal stem cells and 2) Differentiation of 
mesenchymal stem cells were highlighted as focus areas. All studies are shown in Table 2 below: 




















29 No Varied stable Decrease fewer, 
smaller 
Feng et al 33 N/A Decreased N/A Decrease N/A 
Aksoy et 
al 
29 no Decreased stable Decrease n/a 
Fossett et 
al 





41 n/a Decreased n/a Decrease n/a 
Zaim et al 18 n/a Varied n/a Decrease n/a 
Mendez et 
al 
12 n/a Decreased n/a Decrease n/a 
Justesen et 
al 
34 n/a Remained 
stable 
n/a n/a n/a 
Stolzing et 
al 
33 n/a Varied Decrease Decrease fewer, 
smaller 
Table 2 – Table of included key studies in this review [28,29,30,31,32,33,34,35,36]. 
 
Effects of ageing on the characterisation of mesenchymal stem cells 
Three studies were eligible in assessing the effect of ageing on characterisation of hMSC based on being able to 
contribute to at least two out of three of the International Society for Cellular Therapy (ISCT) characterisation 
criteria: 
 (1) adherence to plastic; (2) differentiation into chondrocytes, osteoblasts, and adipocytes under standard in vitro 
differentiating conditions; and (3) expression of surface markers CD105, CD73, and CD90, in the absence of 
haematopoetic markers CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR. 
Sample size varied from 29 to 33 participants and all three were cross sectional. 
Choudhery found there to be no difference in finding the three characterisation criteria in all age groups.  The 
study of 29 participants were divided into three categories; <30, 35-55 and >60. The mean age for the <30 
category was 25.5 and child donors did not participate. All hMSC displayed identical characteristics, those 
being plastic adherent growth, differentiation into chondrocytes, osteoblasts, and adipocytes under standard in 
vitro differentiating conditions; and (3) expression of surface markers. CD14, CD19, that aged hMSC can be 
characterised by the presence of greater mRNA levels of the tumour suppressor gene p16 and apoptosis 
inducing gene p21 (p<0.05). In addition, higher levels of the marker senescence-associated b-galactosidase and 
lower levels of super oxidase dismutase, an antioxidant that counteracts the actions of reactive oxygen species 
were found to be indicators of aging. There was no variability in expression of surface markers with age and 
hMSC were positive for the characterisation requirement MSC markers (CD44, CD73, CD90, CD105) but lack 
expression of hematopoietic markers (CD3, CD14, CD19, CD34,CD45). The study also showed that the number 
of cells per gram and colony forming units as well as cell doublings per unit time decreased with MSC and 
donor age (p<0.01) [28]. 
Stolzing found an age-related reduction in the expression of MSC cell surface markers CD90, CD105, and 
STRO-1, and an increase in CD44 as well as a varied differentiation potential with age. Bone marrow hMSC 
were obtained for the study by aspiration through the posterior iliac crest of all donors [36]. The age range of the 
33 donors was between 5-55 years. However, Fosset measured cell surface characterisation of hMSC of 
different donor ages and found no age related changes in cell surface marker expression [31].  
Aksoy’s results showed no significant change in plastic adherence with older hMSC, lineage differentiation 
capacity decreased and expression of surface markers was found to have been present on cells of all ages. The 
presence of surface markers CD105, CD90, CD73, CD45, and CD34 were present on all hMSC. These results 
were yielded from the bone marrow hMSC of five different age groups of similar sample sizes: infants(0–3 
years of age, n=6), children (ages >3–12 years, n=6), adolescents (ages >12–19 years, n=6), early adults (ages 
>19–35 years, n=6), and mid adults (ages >35–50 years, n=5). They also found that hMSC isolated from 
younger donors, had higher cellular metabolic activity and proliferation rate than older donor cells [30]. 
Effects of ageing on the proliferation of mesenchymal stem cells 
Seven studies confirmed a decrease in proliferation of hMSC in relation to age.[28, 31, 33]. Fosset and Zaim all 
yielded a p value <0.05 when comparing age to population doubling whereas, Zaim produced a p value of < 
0.001. All other seven studies remarked on a clear decrease in MSC proliferation with age. 
Effects of ageing on the differentiation of mesenchymal stem cells 
Eight eligible studies were identified to assess the effects of ageing on the differentiation of mesenchymal stem 
cells. Sample sizes ranged from 12 – 41 participants. 
Of the eight studies, two showed a decreased osteogenic potential coupled with an increased adipogenic 
preference incurring with aged cells. [28] and [36] found there to be decreased osteogenic differentiation in 
favour of increased adipogenic differentiation in older donor hMSC. 
Stolzing found that ‘stressing’ cells with H2O2 to mimic reactive oxygen species also lead to an overall 
decrease in osteogenic differentiation of hMSC, implying the effect of age on the differentiation of hMSC. This 
effect was also mediated by a dysfunction in receptors VDR, GR and Notch-1 which are less bioavailable as 
cells age. These receptors are key to the process of osteogenesis in humans. In addition, Stolzing found that 
adult hMSC (>18 yrs) had the same apoptosis rate as young hMSC (<18 yrs), however, aged hMSC (50-55 yrs) 
displayed significantly increased levels of apoptosis compared to the others (p< 0.001) [36]. 
Zaim compared bone marrow derived hMSC from three groups; (0–12 years, n=6) adult (25–50 years, n=6) and 
old (> 60 years, n=6). They found slightly different results that adipogenic (p <0.001) and osteogenic 
differentiation preference decreased with age, whereas chondrogenic potential did not change. The comparison 
 between the child and adult donor chondrogenic differentiation potential was p>0.05 and therefore not 
statistically significant [33]. 
Four other studies showed a general decrease in differentiation potential of hMSC with age [29,30,32,34]. Feng 
tested dental pulp human mesenchymal cells and found that part of an ageing MSC profile was a decline in 
differentiation. Fourteen patients between the ages of 50- 83 years were tested in this study and they also found 
increased senescence-associated b-galactosidase activity in aged hMSC (p<0.05) and more cells occurring in the 
G0/G1 resting phases than in younger MSC donors [29]. 
Discussion 
Though ageing of hMSC is a topic of interest for research, there are not enough reliable clinical studies to 
categorically explain the effects of ageing on hMSC. There were a high degree of heterogeneity of published 
studies in this systematic review. In addition, the sample size range was low at 12-41 participants which would 
make these conclusions preliminary. 
Effect of ageing on characterisation of mesenchymal stem cells 
Based on this review, the effect of ageing on characterisation of mesenchymal stem cells is that adherence to 
plastic is not affected by age of cells. MSC from all age groups displayed identical morphology and all exhibited 
appropriate adherence to plastic [28,30]. 
Furthermore, four out of nine studies showed decreased differentiation into osteoblasts, adipocytes or 
chondrocytes. However, lineage differentiation remained stable in Justenson’s study and favoured the 
adipogenic profile over the osteogenic profile in two studies. It is hypothesized that this occurs as the body ages 
to reduce bone fortification as the osteogenic profile is more sensitive to reactive oxygen species which 
accumulate with age. 
The presence of surface markers CD105, CD73, and CD90, in the absence of haematopoetic markers were 
CD45, CD34, CD14, CD11b, CD79α, CD19, and HLA-DR were seen to decrease in both Fossett and Stolzing’s 
studies. In particular, both studies showed a consistent presence of the CD105 marker across all ages [31,36]. 
Fossett tested MSC derived from the synovial fat pad of 14 participants (four females, seven males) and found 
there to be a difference in gender. Females had a higher cell surface marker population than men (p<0.05). In 
addition, results showed strong existence of CD44, CD73 and CD105, and absence of CD45, CD54, CD80, 
CD90, CD106, CD166, and STRO-1, some of which are the haematopoietic markers outlined by the 
International Society for Cellular Therapy (ISCT) characterisation criteria. 
D’Ippolito also found a decline in proliferation of MSC with age but also a loss of differentiation and 
multipotentiality. In this study of 41 participants, increasing age yielded both fewer and smaller colony forming 
units (p<0.001) [32]. 
The cumulative results of these studies show that the effect of ageing on characterisation of hMSC remains 
inconclusive. 
Effect of ageing on differentiation of mesenchymal stem cells 
Based on this review, four studies showed a decrease in lineage differentiation with age of MSC. 
Studies have shown that older hMSC have a slower differentiation and proliferation rate to younger hMSC [33]. 
Zaim compared the proliferation rate of hMSC from children to adults and found that as donor age increased the 
population doubling rate of the hHMSC reduced. The incidence of morphological changes increased in cells 
obtained from older donors. Though this study showed statistically significant results of the osteogenic and 
neural differentiation potential of hMSC decreasing with donor age (p<0.001), the sample size was 18 and 
therefore less reliable.  
Justesen used 34 participant samples from bone marrow aspirations from the posterior superior iliac spine. Their 
study found no age related effects on osteogenic or adipogenic differentiation or the associated mRNA levels, 
with the conclusion that aging did not alter the differentiation potential of hMSC [35]. 
 The effect of age on the differentiation of hMSC to the osteogenic lineage has been most researched, and studies 
show that fewer osteoprogenitors are present with increasing age [37]. Three studies showed that both osteoblast 
differentiation and bone formation were reduced in more aged hMSC. Some studies also established that ageing 
causes a change in differentiation profile as well as ability to differentiate into lineages These studies found that 
adipocyte lineage differentiation was favoured over osteoblast differentiation in aged hMSC. It is believed that 
the reason for preference over adipocyte differentiation occurs due to reactive oxygen species and microRNAs 
that accumulate over time targeting regulatory factors Runt-2, Osterix, PPARү and C/EBPα [38]. However, 
other studies confirmed an overall reduction in differentiation to adipogenesis when compared to younger MSC 
donors [39,40]. 
Limitations 
The review had a number of limitations commonly associated with systematic reviews of the literature [41]. The 
sample size for all studies was poor with the range being 12 – 41 participants. Furthermore, eight out of the nine 
studies did not control for gender or co-morbidities. There may also have been missed studies as the database 
search did not cover articles where the full text was not available.  
Conclusion 
In conclusion, this review suggests that there may be some evidence for the effects of ageing on decreasing or 
altering the differentiation potential of hMSC, however, there is no suggestive evidence on age changing key 
characterisation indicators such as plastic adherence and cell surface marker expression. It is important that 
these important questions are addressed to allow the identification of the optimal treatment for each clinical 
situation, and to allow stem cell applications to become more accepted in clinical practice [42-44].  
It is surprising that more viable studies on the effects of ageing on the characterisation and differentiation of 
hMSC could not be found. Further study needs to be conducted on the effective characterisation of hMSC and 
more accurate investigation into the lineage differentiation of terminally differentiated cells including 
intermediate progenitors and external environmental factors that modulate the differentiation. 
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